Aurora Kinase Inhibitors

Cat.No.	Product Name	Information	Product Use Citations
S1451	TCS7010 (Aurora A Inhibitor I)	TCS7010 (Aurora A Inhibitor I) is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B, and triggers apoptosis through the ROS-mediated UPR signaling pathway.	Cell Death Discov, 2025, 11(1):266 Cell Tissue Res, 2025, 10.1007/s00441-025-03992-0 Int J Mol Sci, 2022, 23(24)15573
S2719	AMG-900	AMG 900 is a potent and highly selective pan-Aurora kinases inhibitor for Aurora A/B/C with IC50 of 5 nM/4 nM /1 nM. It is >10-fold selective for Aurora kinases than p38α, Tyk2, JNK2, Met and Tie2. Phase 1.	Sci Rep, 2025, 15(1):3211 Cell, 2024, 187(1):184-203.e28 Nat Commun, 2024, 15(1):10170
S1454	PHA-680632	PHA-680632 is a potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. This compound has 10- to 200-fold higher IC50 for FGFR1, FLT3, LCK, PLK1, STLK2, and VEGFR2/3.	Sci Rep, 2024, 14(1):12470 Heliyon, 2023, 9(7):e17386 Signal Transduct Target Ther, 2022, 7(1):97
S2744	CCT137690	CCT137690 is a highly selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 15 nM, 25 nM and 19 nM. It has little effect on hERG ion-channel.	J Biol Chem, 2025, 301(10):110653 Cancer Lett, 2024, 604:217258 Sci Rep, 2024, 14(1):8200
S2740	GSK1070916	GSK1070916 is a reversible and ATP-competitive inhibitor of Aurora B/C with IC50 of 3.5 nM/6.5 nM. It displays >100-fold selectivity against the closely related Aurora A-TPX2 complex. Phase 1.	Int J Biol Macromol, 2025, 292:139119 PLoS One, 2024, 19(1):e0295629 Cell Chem Biol, 2023, 30(8):987-998.e24
S1154	SNS-314	SNS-314 is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively. It is less potent to Trk A/B, Flt4, Fms, Axl, c-Raf and DDR2. Phase 1.	Cell Chem Biol, 2023, 30(8):987-998.e24 Res Sq, 2023, rs.3.rs-2570204 Haematologica, 2022, 10.3324/haematol.2022.280884
S2718	TAK-901	TAK-901 is a novel inhibitor of Aurora A/B with IC50 of 21 nM/15 nM. It is not a potent inhibitor of cellular JAK2, c-Src or Abl. Phase 1.	Adv Biol Regul, 2025, 95:101072 Sci Rep, 2024, 14(1):8200 Cell Chem Biol, 2023, 30(8):987-998.e24
S1171	CYC116	CYC116 is a potent inhibitor of Aurora A/B with K_i of 8.0 nM/9.2 nM, is less potent to VEGFR2 (K_i of 44 nM), with 50-fold greater potency than CDKs, not active against PKA, Akt/PKB, PKC, no effect on GSK-3α/β, CK2, Plk1 and SAPK2A. Phase 1.	Sci Rep, 2024, 14(1):4303 Cell Chem Biol, 2023, 30(8):987-998.e24 Proc Natl Acad Sci U S A, 2022, 119(15):e2122512119
S1051^New	AZD1152(Barasertib)	AZD1152 (Barasertib) is a selective inhibitor of Aurora B with K_i of 0.36 nM.	ProQuest , 2023, 30683696 Anticancer Res, 2018, 38(3):1407-1414 PLoS One, 2014, 9(7):e102741
S8699	SNS-314 Mesylate	SNS-314 Mesylate is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively and less potent to Trk A/B, Flt4, Fms, Axl, c-Raf and DDR2.	bioRxiv, 2025, 2025.09.17.676776 Haematologica, 2022, 10.3324/haematol.2022.280884 Cancers (Basel), 2021, 13(6)1205
S8782	LY3295668	LY3295668 (AK-01) is a potent, orally active and specific inhibitor of Aurora A kinase with Ki of 0.8 nM and 1038 nM for AURKA and AURKB, respectively.	Front Biosci (Landmark Ed), 2025, 30(8):41293 J Natl Cancer Inst, 2024, djae091 Med Oncol, 2024, 41(6):142
S1519	CCT129202	CCT129202 is an ATP-competitive pan-Aurora inhibitor for Aurora A, Aurora B and Aurora C with IC50 of 0.042 μM, 0.198 μM and 0.227 μM, respectively. It is less potent to FGFR3, GSK3β, PDGFRβ, etc.	Aging (Albany NY), 2020, 7;12(9):8221-8240 J Pediatr Hematol Oncol, 2019, 41(6):e359-e370 PLoS One, 2014, 9(7):e102741
S9658	SP-96	SP-96 is a potent, selective and non-ATP-competitive inhibitor of Aurora B with IC50 of 0.316 nM. This compound can be used for the research of triple negative breast cancer (TNBC).	Cell Chem Biol, 2023, 30(8):987-998.e24
S6214	H-1152 dihydrochloride	H-1152 dihydrochloride (2HCl) is a membrane-permeable and selective inhibitor of Rho-associated protein kinase (ROCK). H-1152 inhibits ROCK2, PKA, PKC, PKG, AuroraA and CaMK2 with IC50 of 0.0120 μM, 3.03 μM, 5.68 μM, 0.360 μM, 0.745 μM and 0.180 μM, respectively.	Cell Rep Med, 2025, 6(8):102297
S7065	MK-8745	MK-8745 is a potent and selective Aurora A inhibitor with IC50 of 0.6 nM, more than 450-fold selectivity for Aurora A over Aurora B.
S9741	TAS-119	TAS-119 is a potent, selective, and orally active inhibitor of Aurora A, including Aurora B with an IC50 of 1.0 nM and 95 nM, respectively. It exhibits antitumor activities.
E0338	AKI603	AKI-603 is an inhibitor of Aurora kinase A (AurA), which is developed to overcome resistance mediated by BCR-ABL-T315I mutation.
E0342	Aurora kinase Inhibitor II	Aurora kinase inhibitor II, an anilinoquinazoline that is both a potent and selective ATP-competitive inhibitor of Aurora kinase (ARK), has the ability to permeate the cell and is involved in the regulation of the cell cycle, particularly cell division.
E5904^New	6K465	6K465 is a pyrimidine-based inhibitor of Aurora A, that reduces levels of c-MYC and N-MYC oncoproteins. It demonstrates compelling antitumor efficacy.
S2931	Aurora Kinase Inhibitor III	Aurora kinase inhibitor III is a potent inhibitor of Aurora A kinase with an IC50 of 42 nM and has high selectivity for Aurora A over BMX, BTK, IGF-1R, c-Src, TRKB, SYK, and EGFR (IC50s = 386, 3,550, 591, 1,980, 2,510, 887, and >10,000 nM, respectively).
E1651	CD532	CD532 is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. It breaks the native conformation of Aurora-A, drives the degradation of N-Myc in N-Myc-driven cancers, and also exhibits anti-proliferative effects.
E1435	Tinengotinib	Tinengotinib (TT-00420) is a novel multiple kinase inhibitor that strongly inhibits Aurora A/B with IC50 values of 1.2/3.3 nM respectively. It also exhibits potent inhibitory activity on FGFR1/2/3, VEGFR1, JAK1/2, and CSF1R and can be used to treat several prominent signaling pathways in triple-negative breast cancer(TNBC).
S1134	AT9283	AT9283 is a potent JAK2/3 inhibitor with IC50 of 1.2 nM/1.1 nM in cell-free assays; also potent to Aurora A/B, Abl1(T315I).	Biochim Biophys Acta Mol Cell Res, 2025, 1872(7):120001 Clin Exp Med, 2025, 25(1):125 Adv Biol Regul, 2025, 95:101072
S7588	Reversine	Reversine is a potent human A3 adenosine receptor antagonist with K_i of 0.66 μM, and a pan-aurora A/B/C kinase inhibitor with IC50 of 400 nM/500 nM/400 nM, respectively. Also used for stem cell dedifferentiation.	Nat Cell Biol, 2025, 27(1):59-72 EMBO J, 2024, 43(19):4324-4355 Sci Adv, 2024, 10(44):eado6607
S2158	KW-2449	KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 with IC50 of 6.6 nM, modestly potent to FGFR1, Bcr-Abl and Aurora A; little effect on PDGFRβ, IGF-1R, EGFR. Phase 1.	Cancer Cell, 2022, S1535-6108(22)00312-9 Cell Rep Med, 2022, 3(1):100492 Cancer Res, 2022, 82(11):2141-2155
S1181	ENMD-2076	ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to RET, SRC, NTRK1/TRKA, CSF1R/FMS, VEGFR2/KDR, FGFR and PDGFRα. This compound inhibits the growth of a wide range of human solid tumor and hematopoietic cancer cell lines with IC50 from 0.025 to 0.7 μM, which induces apoptosis and G2/M phase arrest. Phase 2.	Int J Biol Macromol, 2025, 292:139119 Cell, 2021, 184(2):334-351.e20 Sci Adv, 2021, 7(4)eabd7851
S7843	BI-847325	BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.	Nat Commun, 2023, 14(1):478 Cancer Res Commun, 2023, 3(10):2170-2181 Med Oncol, 2022, 39(10):144
S2018	ENMD-2076 L-(+)-Tartaric acid	ENMD-2076 L-(+)-Tartaric acid is the tartaric acid of ENMD-2076, selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold more selective for Aurora A than Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα. Phase 2.
E0616	Chiauranib	Chiauranib (CS2164) selectively inhibits multiple kinase targets aurora B kinase (AURKB), colony-stimulating factor 1 receptor (CSF1R), and vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR)/c-Kit , thereby inhibiting the rapid proliferation of tumor cells, enhancing the antitumor immunity, and inhibiting tumor angiogenesis, to achieve the anti-tumor efficacy.
S1272	XL228	XL228 is a protein kinase inhibitor with IC50 of 5 nM, 1.4 nM, 3.1 nM, 1.6 nM, 6.1 nM and 2 nM for wild-type ABL kinase, ABL T315I, Aurora A, IGF-1R, SRC and LYN, respectively.